$MCLE
Medicale Corp.

2024 Q3 Form 10-Q Financial Statement

#000168316824005770 Filed on August 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.540K
YoY Change 26.89%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $8.540K
YoY Change 26.89%
Operating Profit -$9.288K -$8.537K
YoY Change 8.8% 26.77%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.173K $0.00
YoY Change
Pretax Income -$10.46K -$8.540K
YoY Change 22.49% 26.89%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.46K -$8.540K
YoY Change 22.49% 26.82%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 5.920M shares 5.920M shares 5.920M shares
Diluted Shares Outstanding 5.920M shares 5.920M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $160.00
YoY Change
Cash & Equivalents $159.00 $159.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $159.00 $160.00
YoY Change -0.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $159.00 $160.00
Total Long-Term Assets $0.00 $0.00
Total Assets $159.00 $160.00
YoY Change -0.63% -97.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.410K
YoY Change -81.15%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.14K $26.65K
YoY Change -46.96% -44.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $68.08K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $14.14K $26.65K
Total Long-Term Liabilities $68.08K $0.00
Total Liabilities $82.21K $26.65K
YoY Change 208.48% -44.73%
SHAREHOLDERS EQUITY
Retained Earnings -$159.0K
YoY Change
Common Stock $592.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$82.05K -$26.49K
YoY Change
Total Liabilities & Shareholders Equity $159.00 $160.00
YoY Change -0.63% -97.95%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$10.46K -$8.540K
YoY Change 22.49% 26.82%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.240K
YoY Change 180.27%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.240K
YoY Change 218.15%
NET CHANGE
Cash From Operating Activities -8.240K
Cash From Investing Activities 0.000
Cash From Financing Activities 8.240K
Net Change In Cash 0.000
YoY Change -100.0%
FREE CASH FLOW
Cash From Operating Activities -$8.240K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
7200 usd
CY2022 MCLE Debt Forgiveness By Related Party
DebtForgivenessByRelatedParty
51192 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001827855
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-250025
dei Entity Registrant Name
EntityRegistrantName
Medicale Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1556944
dei Entity Address Address Line1
EntityAddressAddressLine1
9314 Forest Hill Blvd #929
dei Entity Address City Or Town
EntityAddressCityOrTown
Wellington
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33411
dei City Area Code
CityAreaCode
407
dei Local Phone Number
LocalPhoneNumber
245-7339
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5920000 shares
CY2024Q2 us-gaap Cash
Cash
159 usd
CY2023Q3 us-gaap Cash
Cash
159 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
159 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
159 usd
CY2024Q2 us-gaap Assets
Assets
159 usd
CY2023Q3 us-gaap Assets
Assets
159 usd
CY2024Q2 MCLE Due To Related Parties Current1
DueToRelatedPartiesCurrent1
0 usd
CY2023Q3 MCLE Due To Related Parties Current1
DueToRelatedPartiesCurrent1
20480 usd
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2135 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8399 usd
CY2024Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
12000 usd
CY2023Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
12000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14135 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
40879 usd
CY2024Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
68076 usd
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
68076 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 usd
CY2024Q2 us-gaap Liabilities
Liabilities
82211 usd
CY2023Q3 us-gaap Liabilities
Liabilities
40879 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
592 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
592 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
76320 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
76320 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-158964 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117632 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-82052 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-40720 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9288 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8537 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39198 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23366 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9288 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8537 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-39198 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-23366 usd
CY2024Q2 us-gaap Interest Expense Other
InterestExpenseOther
1173 usd
CY2023Q2 us-gaap Interest Expense Other
InterestExpenseOther
0 usd
us-gaap Interest Expense Other
InterestExpenseOther
2134 usd
us-gaap Interest Expense Other
InterestExpenseOther
0 usd
CY2024Q2 us-gaap Other Expenses
OtherExpenses
1173 usd
CY2023Q2 us-gaap Other Expenses
OtherExpenses
0 usd
us-gaap Other Expenses
OtherExpenses
2134 usd
us-gaap Other Expenses
OtherExpenses
0 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10461 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8537 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41332 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23366 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-10461 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-8537 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-41332 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-23366 usd
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 usd
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
455 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10461 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8537 usd
us-gaap Net Income Loss
NetIncomeLoss
-41332 usd
us-gaap Net Income Loss
NetIncomeLoss
-22911 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.00
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.00
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.01
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.00
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
CY2024Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.00
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.00
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-54774 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
51192 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-8259 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11841 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6115 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-17956 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8537 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-26493 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-40720 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-19307 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-60027 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11564 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-71591 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10461 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-82052 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-41332 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-23366 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
455 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6264 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9412 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-20480 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68076 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13499 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
68076 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
13658 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
68076 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13658 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
159 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159 usd
MCLE Debt Forgiveness By Related Party
DebtForgivenessByRelatedParty
0 usd
MCLE Debt Forgiveness By Related Party
DebtForgivenessByRelatedParty
51192 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-158964 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117632 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_z3uTHLpqFAtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<p id="xdx_848_eus-gaap--RevenueRecognitionMultipleElementArrangements_zkPgxlpEQIud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All revenue generated by the Company was done so by operations that have been discontinued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities
DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities
12000 usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities
DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities
12000 usd
CY2024Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
12000 usd
CY2023Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
12000 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-005770-index-headers.html Edgar Link pending
0001683168-24-005770-index.html Edgar Link pending
0001683168-24-005770.txt Edgar Link pending
0001683168-24-005770-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mcle-20240630.xsd Edgar Link pending
medicale_ex3100.htm Edgar Link pending
medicale_ex3200.htm Edgar Link pending
medicale_i10q-063024.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
mcle-20240630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mcle-20240630_def.xml Edgar Link unprocessable
mcle-20240630_pre.xml Edgar Link unprocessable
mcle-20240630_lab.xml Edgar Link unprocessable
medicale_i10q-063024_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending